Quick Answer
Fulcrum Therapeutics, Inc. reported Operating Income of -$84.77 million for fiscal year 2025.
Fulcrum Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$84.77M | -287.1% |
| 2024 | -$21.90M | +80.2% |
| 2023 | -$110.66M | +1.7% |
| 2022 | -$112.56M | -38.9% |
| 2021 | -$81.05M | -13.2% |
| 2020 | -$71.61M | +15.0% |
| 2019 | -$84.22M | -151.4% |
| 2018 | -$33.50M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$21.86M | +13.0% | -10.3% |
| June 30, 2025 | -$19.82M | -137.7% | +2.9% |
| March 31, 2025 | -$20.40M | +31.6% | +18.8% |
| September 30, 2024 | -$25.13M | +8.4% | -147.9% |
| June 30, 2024 | $52.49M | +292.3% | +275.9% |
| March 31, 2024 | -$29.83M | -6.8% | -8.7% |
| September 30, 2023 | -$27.44M | -12.7% | -0.5% |
| June 30, 2023 | -$27.29M | +20.3% | +2.3% |
- Fulcrum Therapeutics, Inc. showed a decrease of -287.1% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Fulcrum Therapeutics, Inc.’s operating income has declined by 153.1% (from -$33.50 million to -$84.77 million).
- The most recent figure is from Fulcrum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: